BIO26-034: Electronic PowerPlan Transforming Blinatumomab Treatment Into a Safe, and Efficient Workflow

View at publisher Summarise with VIRAT
Authors: Yaser Mahfouz, Shehab Fareed Mohamed, Honar Cherif, Anas Ahmad Hamad, Deena Mudawi, Abdulrahman Fadhl Al-Mashdali, Maria Alkhadra, Sara Al Dali, Greeshma Ann Joseph, Sindu Sindu Stanley, Hannan Zadeh, Mohamed Yassin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Blinatumomab is effective for MRD-positive and relapsed/refractory B-ALL but operationally complex: a continuous 24-hour infusion for 28 days followed by a 14-day break. This creates outpatient logistics, monitoring, and scheduling challenges. Manual, free-text orders are inefficient and error-prone; outpatient pumps help, but standardized ordering is still needed. Methods: At the National Center for Cancer Care and Research, the pharmacy team designed a Blinatumomab-specific PowerPlan in Cerner that mirrors the 42-day cycle and automates the full course of care. After the provider selects the intended cycle, the plan adjusts all dates and times automatically. It schedules Day-0 pre-treatment steps and premedication with dexamethasone and paracetamol one hour before the first dose of each cycle, and it generates a single order that covers the entire 28-day continuous infusion with predefined pump and bag-change visits (e.g., Days 1, 3, 5 … 27). Laboratory monitoring is embedded with timed CBC and LFT orders. To avoid unnecessary exposure, PRN medications for CRS and ICANS are intentionally maintained outside the PowerPlan. The result is a standardized, cycle-aware order set that removes free-text variability and aligns pharmacy, nursing, and clinic schedules. Results: Implementation converted a fragmented, manual process into a master schedule visible on a single screen, allowing providers to track precisely which dose is being delivered at any moment. Automated, pre-scheduled dosing eliminated repeated manual verification and shortened order-build time across cycles, while the integrated treatment history created a closed-loop record of prior cycles and cumulative exposure without searching notes or flowsheets. Clear start and end dates synchronized activities across physicians, pharmacists, and nurses, ensuring drug availability and correct timing for outpatient pump and bag changes. In routine use, these features improved operational efficiency, reduced opportunities for ordering and scheduling errors, and strengthened day-to-day coordination of care. Conclusions: A Blinatumomab-specific PowerPlan can standardize a complex regimen, reduce error risk, enhance interdisciplinary workflow, and improve patient safety and efficiency—freeing clinical time to focus on patient care and optimization.

Fields of Study & Subjects

Electronic Health Records Systems Acute Lymphoblastic Leukemia research Pharmaceutical studies and practices

Publication details

Journal / source
Journal of the National Comprehensive Cancer Network
Volume
24
Issue
3.5
Publication date
27 March 2026
Language
EN